0.07
+1.49%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BCAL Diagnostics
Its shares trade on ASX under the ticker BDX.AX. It has been listed since 21 July 2021. In the fiscal year to 30 June 2025, it reported revenue of A$2.8m and a net loss of A$7.2m. At that date it held total assets of A$9.9m and shareholders' equity of A$6.2m.
BCAL Diagnostics Ltd. develops screening tests for the early detection of breast cancer. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-07-21. The Company’s principal activities include the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, including preparation for clinical trials. The company developed a blood screening test to be used alongside breast cancer screening methods. The technology initially complements imaging technologies, such as the mammogram, while it further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location. Its BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring. The firm has partnered with Precion Inc. to optimize protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 21 Jul 2021
- Website
- bcaldiagnostics.com ↗
Leadership
Pay as last reported
- Ms. Jayne ShawExecutive Chairman of the Board, since 2010A$180,000
- Mr. Shane RyanChief Executive Officer
- Mr. Guy RobertsonChief Financial Officer, Company Secretary
- Dr. Amani BatarsehChief Scientific OfficerA$317,519
- Mr. David DarlingNon-Executive Director
- Dr. John HurrellNon-Executive Director, since 2022A$525,578
- Mr. Jonathan TrollipNon-Executive Independent DirectorA$50,229
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BCAL Diagnostics Ltd. develops a novel blood screening test for early breast cancer detection in Sydney, Australia.
- The BCAL test uses lipid biomarkers for breast cancer prevention, screening, and monitoring.
- Partnership with Precion Inc. optimizes clinical study protocols for regulatory approvals globally.
Weaknesses
- The company's IPO was on 21 July 2021, limiting market presence duration.
- BCAL Diagnostics Ltd. focuses solely on breast cancer screening without broader health applications.
- The technology complements imaging methods like mammograms but does not replace them.
Opportunities
- Expansion into global markets with regulatory approvals across multiple jurisdictions.
- Integration of BCAL test with existing mammogram screening protocols worldwide.
- Growing demand for early breast cancer detection methods in the Health Care sector.
Threats
- Competition from established breast cancer screening technologies in the Health Care industry.
- Regulatory delays in obtaining approvals for clinical studies across different countries.
- Dependence on Precion Inc. for optimizing clinical study protocols and procedures.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.